Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
The trial investigates the use of CLN-978, a CD19-directed T cell engager given by subcutaneous injection, for treating adults with moderate to severe Systemic Lupus Erythematosus SLE. This Phase 1b open-label study focuses on evaluating the safety and tolerability of the treatment in patients who have active disease despite prior therapies. The research aims to explore how the drug interacts with the body and its effects on immune biomarkers over 48 weeks. Participants receive CLN-978 through specified doses on certain days, starting with dose escalation cohorts followed by further dose evaluations. The study is non-randomized and open-label, meaning all participants receive the study drug. Treatment is administered subcutaneously, and the study includes two parts Part A focuses on dose escalation and Part B on additional dose evaluation for those who tolerate initial treatment. During the trial, participants undergo regular safety assessments, laboratory tests, and biomarker monitoring for up to 48 weeks. Researchers measure how well patients tolerate the drug, its pharmacokinetics, immunogenicity, and related pharmacodynamic biomarkers. The study lasts until late 2027, with ongoing evaluations to understand the treatments impact on SLE disease activity and patients health.
Actively Recruiting
Psoriatic arthritis PsA is a chronic inflammatory condition affecting joints and skin. This Phase 3 study aims to assess the long-term safety, tolerability, and effectiveness of the drug zasocitinib in adults with active PsA. It includes adults who have completed a previous year-long treatment in related parent studies and evaluates continued treatment over an extended period. Participants who previously took zasocitinib will maintain their assigned dose, while those initially on a different treatment will be randomly assigned to one of two doses of zasocitinib, taken once daily as oral tablets. The study treatment phase lasts up to 104 weeks, followed by a 4-week health monitoring period, totaling about 2 years of participation. During the study, participants will be regularly monitored for side effects, vital signs, and lab tests to assess safety. Researchers will also evaluate treatment effectiveness using criteria like the American College of Rheumatology response and skin improvement scores at multiple time points. After treatment, a follow-up period will ensure participants health is observed for any ongoing effects.